PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer
RESEARCH|Updated:2026-01-29
|
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer
“In the field of early-stage non-small cell lung cancer treatment, researchers have developed an AI-assisted model called PRIME, which integrates clinical-genomic predictors to enhance risk prediction and guide personalized therapy. The model outperforms single liquid biopsy biomarkers and clinical-therapeutic signatures, demonstrating consistent robustness across different clinical scenarios.”
Military Medical ResearchVol. 12, (2025)
Affiliations:
1.Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2.Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
3.Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong, China
4.Key Laboratory of Minimally Invasive Therapy Research for Lung Cancer, Chinese Academy of Medical Sciences, Beijing 100021, China
5.State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Yu Wang, Yong-Bo Xiang, Xiao-Wei Chen, et al. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer[J/OL]. Military Medical Research, 2025, 12.
DOI:
Yu Wang, Yong-Bo Xiang, Xiao-Wei Chen, et al. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer[J/OL]. Military Medical Research, 2025, 12. DOI: 10.1186/s40779-025-00679-z.
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer